Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years ...Middle East

Medscape - News
The full 5-year results of a study of tildrakizumab for psoriasis show a high rate of sustained disease control coupled with a favorable safety profile during more than 5400 patient-years of follow-up. Medscape Medical News

Hence then, the article about tildrakizumab for psoriasis shows durable efficacy over 5 years was published today ( ) and is available on Medscape ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Tildrakizumab for Psoriasis Shows Durable Efficacy Over 5 Years )

Apple Storegoogle play

Last updated :

Also on site :

Most viewed in News